A non - interventional study to follow and evaluate patients with advanced NSCLC who are treated in a second line setting with Erlotinib in a "Real Life" clinical setting
The primary objective of this study is to follow and evaluate patients with advanced NSCLC who have been treated in routine oncology daily practice with Tarceva® as second-line therapy.
• 18 years of age or older
• Histological or cytological documented diagnosed of inoperable, locally advanced, recurrent or metastatic (Stage III or Stage IV).
• Presence of measurable disease (RECIST criteria)
• ECOG performance status of 0-2
• Per regulatory requirement, patient who have received one course of standard systemic chemotherapy.
CHL
for articles/videos/studies
This page provides the list of clinical studies currently registered in the LuxCLIN platform in the different therapeutic areas. By clicking on each study title, more information is displayed concerning the study objective and the participation conditions.
